


글로벌 제약사 파이프라인 분석

- Gilead Sciences -


2022. 10.
국가신약개발사업단

• 질환별 파이프라인



질환분야	개수	비중
Oncology	38	61%
Infectious	17	27%
Immunology	5	8%
Gastrointestinal	1	2%
Metabolic	1	2%
합계	62개	100%

• 물질별 파이프라인



물질	개수	비중
Small molecules	21	34%
Antibody	18	29%
ADC	8	13%
Cell Therapy	8	13%
N/A(Not Applicable)	2	5%
Peptide	1	3%
RNA	1	1.5%
Protein	3	1.5%
합계	62개	100%

• 상세 파이프라인

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
1	Gastrointestinal	Phase 3	GS-99674		cilofexor	Primary sclerosing cholangitis	Small molecules	Farnesoid X receptor(FXR)	FXR agonist	Mono	-
2	Immunology	Phase 1	GS-1427			Inflammatory bowel disease	N/A	Integrin Alpha 4(ITGA 4)/Integrin Beta 7 (ITGB7)	ITGA7/ITGB7 antagonist	Mono	-
3	Immunology	Phase 1	GS-5290			Inflammatory bowel disease	N/A	Tumor Progression locus 2(TPL2)	TPL2 inhibitor	Mono	-
4	Immunology	Phase 1	GS-5718			Inflammatory bowel disease	Small molecules	IL-1 receptor associated kinase 4(IRAK4)	IRAK4 inhibitor	Mono	-
5	Immunology	Phase 1	GS-5718			Lupus	Small molecules	IL-1 receptor associated kinase 4(IRAK4)	IRAK4 inhibitor	Mono	-
6	Immunology	Phase 1	GS-5718			Rheumatoid arthritis	Small molecules	IL-1 receptor associated kinase 4(IRAK4)	IRAK4 inhibitor	Mono	-
7	Infectious	Registration	GS-6207		lenacapavir	HIV, heavily treatment experienced people	Small molecules	HIV capsid protein	Capsid inhibitor	Mono	-
8	Infectious	Registration		Hepcludex	bulevirtide	HDV	Peptide	SLC10A1	SLC10A1 inhibitor	Mono	-
9	Infectious	Phase 3	GS-6207		lenacapavir	HIV pre-exposure prophylaxis	Small molecules	HIV capsid protein	Capsid inhibitor	Mono	-
10	Infectious	Phase 3		Hepcludex	bulevirtide	HDV, finite treatment	Peptide	SLC10A1	SLC10A1 inhibitor	Mono	-
11	Infectious	Phase 2	GS-1703		lefitolimod	HIV	RNA	TLR9	TLR9 agonist	Mono	OncXerna
12	Infectious	Phase 2	GS-5423+GS-2872			HIV	Antibody	Surface Protein gp120	Surface protein gp120 inhibitor	Combination	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
13	Infectious	Phase 2	GS-5894		HIV NNRTI	HIV	Small molecules	Reverse transcriptase	Reverse transcriptase inhibitor	Mono	-
14	Infectious	Phase 2	GS-6207		lenacapavir	HIV, virologically suppressed people	Small molecules	HIV capsid protein	Capsid inhibitor	Mono	-
15	Infectious	Phase 2	GS-6207+ MK-8591		lenacapavir/islatravir	HIV, virologically suppressed people	Small molecules	HIV capsid protein	Capsid inhibitor	Combination	MSD
16	Infectious	Phase 2	GS-9620		vesatolimod	HIV	Small molecules	TLR9	TLR9 agonist	Mono	-
17	Infectious	Phase 2	GS-9688		selgantolimod	HBV cure	Small molecules	TLR8	TLR8 agonist	Mono	-
18	Infectious	Phase 1	GS-5245			COVID-19	Small molecules	RNA directed RNA polymerase	RNA directed RNA polymerase inhibitor	Mono	-
19	Infectious	Phase 1	GS-6207+ GS-5423+ GS-2872			HIV, virologically suppressed people	Small molecules	HIV capsid protein, Surface Protein gp120	Capsid inhibitor, Surface protein gp120 inhibitor	Combination	-
20	Infectious	Phase 1	GS-6207+ GS-9883		lenacapavir/bictegravir oral	HIV, virologically suppressed people	Small molecules	HIV capsid protein	Capsid inhibitor	Combination	MSD
21	Infectious	Phase 1	GS-6212		INSTI	HIV	Small molecules	HIV Integrase	HIV Integrase inhibitor	Mono	-
22	Infectious	Phase 1	GS-9883		long acting bictegravir	HIV	Small molecules	HIV I Integrase	HIV I Integrase inhibitor	Mono	-
23	Infectious	Phase 1				HIV	N/A	N/A	N/A	Mono	Gritstone
24	Metabolic	Phase 2	GS-99674+ GS-0976+ NN9535		cilofexor+firsocostat+semaglutide	Non-alcoholic steatohepatitis (NASH)	Small molecules	Farnesoid X receptor(FXR)	FXR agonist	Combination	Novo Nordisk

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
25	Oncology	Phase 3	GS-0122+ AB154		zimberelimab+ domvanalimab +chemo vs. pembrolizumab +chemo	NSCLC, 1L	Antibody	PD-1, TIGIT	PD-1/TIGIT antagonist	Combination	Arcus Bioscience
26	Oncology	Phase 3	GS-0132	Trodelvy	sacituzumab govitecan-hziy	Metastatic breast cancer	ADC	TROP2	Cytotoxic to cells expressing TROP2	Mono	-
27	Oncology	Phase 3	GS-0132	Trodelvy	sacituzumab govitecan-hziy	Metastatic TNBC (PD-L1-), 1L	ADC	TROP2	Cytotoxic to cells expressing TROP2	Mono	-
28	Oncology	Phase 3	GS-0132	Trodelvy	sacituzumab govitecan-hziy	Metastatic TNBD (PD-L1+), 1L	ADC	TROP2	Cytotoxic to cells expressing TROP2	Mono	-
29	Oncology	Phase 3	GS-0132	Trodelvy	sacituzumab govitecan-hziy	NSCLC, 1L	ADC	TROP2	Cytotoxic to cells expressing TROP2	Mono	-
30	Oncology	Phase 3	GS-0132	Trodelvy	sacituzumab govitecan-hziy	NSCLC, 2-3L	ADC	TROP2	Cytotoxic to cells expressing TROP2	Mono	-
31	Oncology	Phase 3	GS-4721		magrolimab	Acute myeloid leukemia, 1L	Antibody	CD47	CD47 inhibitor	Mono	-
32	Oncology	Phase 3	GS-4721		magrolimab	Acute myeloid leukemia, 1L Unfit	Antibody	CD47	CD47 inhibitor	Mono	-
33	Oncology	Phase 3	GS-4721		magrolimab	Higher risk myelodysplastic syndrome, 1L	Antibody	CD47	CD47 inhibitor	Mono	-
34	Oncology	Phase 3	KTE-C19	Yescarta	axi-cel	Follicular lymphoma, high-risk, 2L	Cell Therapy	CD19	CAR-T	Mono	-
35	Oncology	Phase 3	KTE-C19	Yescarta	axi-cel	Large B-cell lymphoma, High-risk, 1L	Cell Therapy	CD19	CAR-T	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
36	Oncology	Phase 3	MEDI4736+ AB154		durvalumab± domvanalimab	NSCLC, stage 3	Antibody	PD-L1, TIGIT	PD-L1 inhibitor/TIGIT antagonist	Combination	Arcus Bioscience, AstraZeneca
37	Oncology	Phase 3	GS-0122+ AB154		zimberelimab+ domvanalimab +chemo vs. pembrolizumab +chemo	NSCLC, 1L	Antibody	PD-1, TIGIT	PD-1/TIGIT antagonist	Combination	Arcus Bioscience
38	Oncology	Phase 2	AB928		Etrumadenant	Colorectal cancer, metastatic	Small molecules	Adenosine A2 recep tor(ADORA2)	ADORA2 antagonist	Combination	Arcus Bioscience
39	Oncology	Phase 2	GS-0122+ AB154		zimberelimab+ domvanalimab± chemo	Upper GI cancer, 1-2L	Antibody	PD-1, TIGIT	PD-1/TIGIT antagonist	Combination	Arcus Bioscience
40	Oncology	Phase 2	GS-0122+ AB154+ AB928		zimberelimab vs. domvanalimab+ zimberelimab vs. zimberelimab+ domvanalimab+ etrumadenant	NSCLC, stage 3	Antibody	PD-1, TIGIT, ADORA2	PD-1/TIGIT/ADORA2 antagonist	Combination	Arcus Bioscience
41	Oncology	Phase 2	GS-0122+ AB680		zimberelimab+ quemliclustat+ gemcitabine/ nab-paclitaxel	Pancreatic ductal adenocarcinoma, metastatic	Small molecules	PD-1, CD73, RRM, Tubulin	PD-1 antagonist, CD7/ RRM/Tubulin inhibitor	Combination	Arcus Bioscience
42	Oncology	Phase 2	GS-0132	Trodelvy	sacituzumab govitecan-hziy	NSCLC, 1L	ADC	TROP2	Cytotoxic to cells expressing TROP2	Mono	-
43	Oncology	Phase 2	GS-0132	Trodelvy	sacituzumab govitecan-hziy	Solid tumors	ADC	TROP2	Cytotoxic to cells expressing TROP2	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
44	Oncology	Phase 2	GS-0132	Trodelvy	sacituzumab govitecan-hziy	Urothelial carcinoma, metastatic, 1L	ADC	TROP2	Cytotoxic to cells expressing TROP2	Mono	-
45	Oncology	Phase 2	GS-4721		magrolimab	Colorectal cancer, metastatic	Antibody	CD47	CD47 inhibitor	Mono	-
46	Oncology	Phase 2	GS-4721		magrolimab	Head and neck squamous cell carcinoma	Antibody	CD47	CD47 inhibitor	Mono	-
47	Oncology	Phase 2	GS-4721		magrolimab	Multiple myeloma	Antibody	CD47	CD47 inhibitor	Mono	-
48	Oncology	Phase 2	GS-4721		magrolimab	Solid tumors	Antibody	CD47	CD47 inhibitor	Mono	-
49	Oncology	Phase 2	GS-4721		magrolimab	TNBC	Antibody	CD47	CD47 inhibitor	Mono	-
50	Oncology	Phase 2	KTE-C19	Yescarta	axi-cel	Large B-cell lymphoma, 1L	Cell Therapy	CD19	CAR-T	Mono	-
51	Oncology	Phase 2	KTE-C19	Yescarta	axi-cel	Large B-cell lymphoma, outpatient, 2L	Cell Therapy	CD19	CAR-T	Mono	-
52	Oncology	Phase 2	KTE-X19	Tecartus	brexucel	Acute lymphocytic leukemia, pediatric	Cell Therapy	CD19	CAR-T	Mono	-
53	Oncology	Phase 2	KTE-X19	Tecartus	brexucel	B-cell malignancies, rare	Cell Therapy	CD19	CAR-T	Mono	-
54	Oncology	Phase 1/2	AB928		etrumadenant	Prostate cancer, metastatic castrate-resistant	Small molecules	Adenosine A2 receptor(ADORA2)	ADORA2 antagonist	Combination	-
55	Oncology	Phase 1/2	GS-4721		magrolimab	Diffuse large B-cell lymphoma	Antibody	CD47	CD47 inhibitor	Mono	-
56	Oncology	Phase 1	GS-0122+ AB308		zimberelimab +AB308	Advanced cancers	Antibody	PD-1, TIGIT	PD-1/TIGIT antagonist	Combination	Arcus Bioscience

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
57	Oncology	Phase 1	GS-0174			Transplant conditioning Regimen	Antibody	c-Kit	c-Kit inhibitor	Mono	-
58	Oncology	Phase 1	GS-1811			Advanced cancers	Antibody	CC chemokine receptor 8(CCR8)	CCR8 antagonist	Mono	-
59	Oncology	Phase 1	GS-3583			Advanced cancers	Protein	FMS-like tyrosine kinase 3(FLT3)	FLT3 agonist	Mono	-
60	Oncology	Phase 1	GS-9716			Advanced cancers	Small molecules	Myeloid leukemia 1 (MCL1)	MCL1 inhibitor	Mono	-
61	Oncology	Phase 1	KITE-222			Acute myeloid leukemia, relapsed/refractory	Cell Therapy	C-type lectin-like molecule 1(CLL-1)	Cytotoxic to cells expressing CLL-1	Mono	-
62	Oncology	Phase 1	KITE-363			Diffuse large B-cell lymphoma, 3L+	Cell Therapy	CD19, CD20	Cytotoxic to cells expressing CD19/CD20	Mono	-